

**REMARKS**

Applicant elects Group I, claims 1-42 and 52-56, which are drawn to an inhibitor of asparaginyl endopeptidase, pharmaceutical preparations comprising same, methods of making same and methods of modulating an immune response or reducing protein processing in a patient or cell using same. Further, Applicant elects the species, "treatment of autoimmune disease," as shown in claims 3, 4, 13, 24, 25 and 40 as required under 35 USC section 121.

Please cancel claims 5-7, 21, and 26-27 because they do not claim the elected species above. Claim 40 has been amended and the phrase "or an allergic or hypersensitivity reaction" has been deleted because it is not part of the elected species. Therefore, the following claims are pending: 1-4, 8-20, 22-25, 28-42, and 52-56.


Applicant also requests that the Examiner's request for new and formal drawings be held in abeyance until such time as the patent application is allowed. MPEP 608.02(b); 37 CFR 1.85(c).

In conclusion, the Examiner is respectfully requested to withdraw or modify the restriction requirement and examine pending claims 1-4, 8-20, 22-25, 28-42, and 52-56.

Accordingly, examination of this application on the merits is respectfully requested.

Respectfully submitted,

Dated: 03 November 2003

  
\_\_\_\_\_  
Guy P. Smith, Reg. No. 20,142  
Attorney for Applicant

**OPPENHEIMER WOLFF & DONNELLY LLP**  
233 Wilshire Blvd., Suite 700  
Santa Monica, Ca 90401  
Tel: 310.319.5414